Regentis Biomaterials Ltd. (RGNT) stock
RGNTNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
$1.14−0.08 (-6.56%)
Close on Nov 18, 2026Market cap $5.90MP/E –Yield –
Regentis Biomaterials r&d expenses
Research and development expenses are spending on new products and technology.
No r&d expenses figures for Regentis Biomaterials
Regentis Biomaterials has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?